Supporting Information

for

Efficient carbon-Ferrier rearrangement on glycals mediated by ceric ammonium nitrate: Application to the synthesis of 2-deoxy-2-amino-Cglycoside

Alafia A. Ansari, Y. Suman Reddy and Yashwant D. Vankar*

Address: Department of Chemistry, Indian Institute of Technology Kanpur 208 016, India

Email: Yashwant D. Vankar - vankar@iitk.ac.in

*Corresponding author

Analytical data and copies of the ¹H NMR and ¹³C NMR spectra of all new compounds

Contents

Experimental section: General methods	S2
Analytical data of the compounds	S3–S10
Copies of NMR spectra	S11–S26

Experimental section

General methods: All the experiments have been carried out in oven-dried apparatus and in dry solvents under nitrogen atmosphere unless indicated otherwise. Commercial grade solvents were dried by methods known in literature and stored over 4 Å molecular sieves. TLC plates were prepared by using thin layers of silica gel on microscopic slides and the visualization of spots was effected by exposure to iodine or spraying with 10% H₂SO₄ and charring. Column chromatography was performed over silica gel (100–200 mesh) by using hexane and ethyl acetate as an eluent. Optical rotations were measured with a polarimeter at 28 °C in the indicated solvents. IR spectra were recorded as a thin film and expressed in cm⁻¹. ¹H NMR (400 or 500 MHz) and ¹³C NMR (100 or 125 MHz) spectra were recorded with CDCl₃ as a solvent. Chemical shifts were reported in ppm downfield to tetramethylsilane and coupling constants expressed in Hertz (Hz). Splitting patterns were assigned as s (singlet), d (doublet), dd (doublet of doublet), dt (doublet of triplet), td (triplet of doublet), m (multiplet) or br (broad). Mass spectra were obtained by Q-TOF by using the electrospray ionisation method.

General procedure for Ferrier rearrangement of glycals by using CAN: A glycal (0.368 mmol) was dissolved in freshly dried CH₃CN (3 mL) under N₂ atmosphere. To this solution was added a nucleophile (0.736 mmol), followed by ceric ammonium nitrate (202 mg, 0.368 mmol). The reaction mixture was stirred at room temperature for the time indicated. After complete consumption of glycal (TLC monitoring), the reaction mixture was poured into a saturated NaHCO₃ solution (5 mL), and extracted with ethyl acetate (3×5 mL). Combined organic extracts were washed with brine (1×10 mL), dried over Na₂SO₄, and concentrated under vacuum. The obtained residue was purified by column chromatography.

(3*S*,6*S*)-6-Allyl-3-(benzyloxy)-3,6-dihydro-2*H*-pyran (2g): Glycals 1g and 1h were subjected to the reaction following the general procedure described above. 2g was obtained in 71% and 61% yields, respectively, as a colorless oil: $R_f = 0.6$ (hexane/EtOAc = 19:1); $[\alpha]_D^{28} = +71.4$ (*c* 0.70, CH₂Cl₂); IR (neat) v_{max} : 3032, 2921, 2859, 1641, 1496, 1454, 1100 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.35–7.25 (m, 5H), 5.93 (dd, *J* = 3.4, 10.8 Hz, 1H), 5.85–5.77 (m, 2H), 5.12–5.07 (m, 2H), 4.63 (d, *J* = 11.7 Hz, 1H), 4.57 (d, *J* = 11.7 Hz, 1H), 4.16–4.07 (m, 3H), 3.48 (dd, *J* = 7.1, 10.0 Hz, 1H), 2.29–2.25 (m, 2H); ¹³C NMR (125 MHz, CDCl₃): δ 138.4, 134.2, 131.7, 128.5, 127.8, 127.6, 127.0, 117.4, 73.6, 71.1, 69.6, 67.1, 39.4; HRMS calcd for C₁₅H₁₈NaO₂ [M + Na]⁺ 253.1204, Found: 253.1208.

(2R,3S,6R)-6-Allyl-2-((tert-butyldiphenylsilyloxy)methyl)-3,6-dihydro-2H-pyran-3-yl

acetate (2i) : Compound 2i was obtained from glycal 1i (50 mg, 0.11 mmol) in 67% yield (36 mg) as a colorless oil: $R_f = 0.4$ (hexane/EtOAc = 19:1); $[\alpha]_D^{28} = +36.0$ (*c* 1.00, CH₂Cl₂); IR (neat) v_{max} : 3072, 2931, 2858, 1741, 1472, 1428, 1370, 1235, 1112 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.68–7.66 (m, 4H), 7.43–7.36 (m, 6H), 5.90–5.77 (m, 3H), 5.13–5.07 (m, 3H), 4.18 (*br* s, 1H), 3.91 (dd, *J* = 5.1, 10.9 Hz, 1H), 3.79–3.75 (m, 2H), 2.43 (dd, *J* = 6.3, 13.7 Hz, 1H), 2.29 (dd, *J* = 7.7, 13.7 Hz, 1H), 2.00 (s, 3H), 1.05 (s, 9H); ¹³C NMR (125 MHz, CDCl₃): δ 170.5, 135.7, 134.3, 133.4, 129.7, 127.7, 123.3, 117.4, 73.5, 70.7, 65.3, 63.2, 38.4, 26.8, 21.2, 19.3; HRMS calcd for C₂₇H₃₈NO₄Si [M + NH₄]⁺ 468.2570, Found: 468.2574.

((2*S*,5*R*)-5-Allyl-2,5-dihydrofuran-2-yl)methyl acetate (2l): Ribose glycal 1l (50 mg, 0.25 mmol) was converted to 2l (28mg, 62%). Colorless oil: $R_f = 0.5$ (hexane/EtOAc = 9:1); $[\alpha]_D^{28} = +110.0$ (*c* 0.60, CH₂Cl₂); IR (neat) v_{max} : 2923, 2853, 1732, 1445, 1011 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 5.90 (dt, J = 1.7, 10.6 Hz, 1H), 5.85–5.77 (m, 2H), 5.25–5.21 (m, 1H), 5.13–5.07 (m, 2H), 4.19–4.15 (m, 1H), 4.11 (dd, J = 4.9, 11.4 Hz, 1H), 3.53 (dd, J = 6.6, 11.4

Hz, 1H), 2.37–2.24 (m, 2H), 2.05 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 170.1, 133.9, 133.6, 124.5, 117.7, 73.1, 65.1, 65.0, 38.7, 31.3; HRMS calcd for C₁₀H₁₄NaO₃ [M + Na]⁺ 205.0841 Found: 205.0846.

Compound 3: The glycal **1a** (100 mg, 0.37 mmol) was treated with TMSCN (0.09 mL, 0.74 mmol) by using the general procedure to afford **3** (74 mg, 77%) as a colorless oil: $R_f = 0.5$ (hexane/EtOAc = 3:1); IR (neat) v_{max} : 3645, 3473, 2923, 2133, 1732, 1434, 1370, 1220, 1092 cm⁻¹; ¹H NMR (5:1 mixture of diastereomers, 500 MHz, CDCl₃): δ 6.35 (m, 1H, minor isomer), 6.27 (dd, J = 2.5, 11.3 Hz, 1H, major isomer), 6.14 (m, 1H, minor isomer), 6.08 (dd, J = 1.9, 11.3 Hz, 1H, major isomer), 5.19 (br s, 2H, major isomer), 5.02 (br s, 2H, minor isomer), 4.23 (m, 3H, major isomer), 3.98 (m, 3H, minor isomer), 2.14-2.07 (m, 3H, both isomers); ¹³C NMR (5:1 mixture of diastereomers, 100 MHz, CDCl₃): δ 172.1, 171.9, 170.3, 170.1, 132.0, 129.8, 123.8, 122.4, 116.2, 72.1, 64.3, 62.5, 62.1, 60.2, 58.1, 57.6, 22.5, 22.1, 20.5, 20.4; HRMS calcd for C₁₁H₁₃NNaO₅ [M + Na]⁺ 262.0691, Found: 262.0691.

Compound 4: The glycal **1b** (100 mg, 0.37 mmol) was treated with TMSCN (0.09 mL, 0.74 mmol) by using the general procedure to afford **4** (60 mg, 62%) as a colorless oil: $R_f = 0.5$ (hexane/EtOAc = 3:1); IR (neat) v_{max} : 3640, 3477, 2925, 2132, 1735, 1438, 1369, 1209, 1105 cm⁻¹; ¹H NMR (4:1 mixture of diastereomers, 500 MHz, CDCl₃): δ 6.33 (m, 1H, minor isomer), 6.24 (dd, J = 1.7, 8.0 Hz, 1H, major isomer), 6.04 (m, 1H, both isomers), 5.13 (br s, 2H, both isomers), 4.25 (m, 3H, major isomer), 4.03 (m, 3H, minor isomer), 2.14-2.07 (m, 3H, both isomers); ¹³C NMR (125 MHz, CDCl₃): δ 171.3, 170.7, 170.1, 126.5, 126.4, 124.7, 115.3, 115.2, 72.2, 72.0, 62.7, 62.2, 62.0, 60.8, 21.9, 20.8, 20.7; HRMS calcd for C₁₁H₁₃NNaO₅ [M + Na]⁺ 262.0691, Found: 262.0691.

Compound 5: The glycal **1a** (100 mg, 0.37 mmol) was treated with TMSN₃ (0.10 mL, 0.74 mmol) by using the general procedure to afford **5** (74 mg, 69%) as a colorless oil: $R_f = 0.5$ (hexane/EtOAc = 4:1); IR (neat) v_{max} : 2922, 2851, 2104, 1746, 1646, 1454, 1371, 1223 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 6.52-6.48 (m, 1H), 5.94 (d, J = 10.3 Hz, 1H), 5.79-5.76 (m, 1H), 5.56 (br s, 1H), 5.32-5.30 (m, 1H), 5.16-5.14 (m, 1H), 5.10-5.07 (m, 1H), 4.89-4.87 (m, 1H), 4.80-4.78 (m, 1H), 4.38-4.05 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 170.8, 170.7, 170.2, 169.8, 147.1, 129.7, 126.4, 96.5, 84.4, 74.4, 70.6, 68.9, 68.1, 67.6, 64.6, 62.6, 61.9, 53.4, 21.0, 20.8, 20.6; HRMS calcd for C₁₀H₁₃N₃NaO₅ [M + Na]⁺ 278.0753, Found: 278.0754.

Compound 6: The glycal **1b** (100 mg, 0.37 mmol) was treated with TMSN₃ (0.10 mL, 0.74 mmol) by using the general procedure to afford **6** (61 mg, 59%) as a colorless oil: $R_f = 0.5$ (hexane/EtOAc = 4:1); IR (neat) v_{max} : 2920, 2851, 2117, 1747, 1660, 1434, 1371, 1223 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 6.45 (d, J = 6.3 Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H), 5.55-5.23 (m, 3H), 4.94-4.91 (m, 1H), 4.72 (m, 1H), 4.35-4.10 (m, 8H), 3.83-3.79 (m, 1H), 2.16-2.00 (m, 3H, 4 isomers); ¹³C NMR (100 MHz, CDCl₃): δ 170.6, 170.4, 170.3, 170.2, 169.8, 169.5, 145.5, 98.9, 96.9, 87.2, 72.8, 69.5, 69.0, 68.6, 66.6, 66.2, 65.6, 63.9, 63.8, 62.2, 62.0, 60.9, 55.9, 53.1, 20.9, 20.8, 20.7, 20.6; HRMS calcd for C₁₀H₁₃N₃NaO₅ [M + Na]⁺ 278.0753, Found: 278.0751.

((2*R*,3*S*)-3-Acetoxy-3,6-dihydro-2*H*-pyran-2-yl)methyl acetate 7: The glucal 1a (100 mg, 0.37 mmol) was treated with Et₃SiH (0.12 mL, 0.74 mmol) by using the general procedure to afford 7 (38 mg, 43%) as a colorless oil: $R_f = 0.4$ (hexane/EtOAc = 4:1); $[\alpha]_D^{28} = +81.4$ (*c* 0.70, CHCl₃); IR (neat) v_{max} : 2922, 2850, 1735, 1445, 1368, 1226, 1022 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 5.93 (dd, J = 1.7, 10.3 Hz, 1H), 5.74 (dd, J = 2.3, 10.3 Hz, 1H), 5.24 (m, 1H), 4.21-4.14 (m, 4H), 3.73-3.69 (m, 1H), 2.09 (s, 3H), 2.06 (s, 3H); ¹³C NMR (125 MHz,

CDCl₃): δ 170.7, 170.1, 126.5, 126.4, 115.3, 72.0, 62.7, 62.2, 20.8; HRMS calcd for C₁₅H₁₈NaO₂ [M + Na]⁺ 237.0739, Found: 237.0732.

(2R,3S,6R)-6-Allyl-2-(benzyloxymethyl)-3,6-dihydro-2H-pyran-3-ol (8): The diacetate 2a (500 mg, 2.0 mmol) was dissolved in dry methanol (10 mL), cooled to 0 °C, and then treated with anhydrous K₂CO₃ (1.38 g, 10.0 mmol). The reaction mixure was stirred at room temperature for 2 hours. The reaction mixture was passed through a silica plug and concentrated. The residue was dissolved in dry toluene (5 mL) and treated with n-Bu₂SnO (747 mg, 3.0 mmol) at 140 °C for 6h by using a Dean–Stark apparatus. The reaction mixture was then cooled to room temperature, and Et₃N (0.21 mL, 1.50 mmol), TBAI (812 mg, 2.2 mmol) and BnBr (0.95 mL, 8.0 mmol) were added. The resulting solution was heated to 120 °C for 2 h, poured into 1 N HCl (10 mL), and extracted with ethyl acetate (3×10 mL). The extracted material was washed with brine (1 \times 20 mL), dried over Na₂SO₄, and concentrated under vacuum. The crude residue was purified by column chromatography to afford product 8 (355 mg, 69%) as a pale yellow liquid: $R_f = 0.6$ (hexane/EtOAc = 4:1); $[\alpha]_D^{28} = -21.1$ (c 1.80, CH₂Cl₂); IR (neat) v_{max} : 3430, 3032, 2924, 2870, 1641, 1496, 1453, 1255, 1091 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.36–7.27 (m, 5H), 5.87–5.77 (m, 3H), 5.12–5.06 (m, 2H), 4.58 (s, 2H), 4.22–4.18 (m, 1H), 4.10–4.07 (m, 1H), 3.72 (dd, J = 5.2, 8.5 Hz, 1H), 3.70 (td, J = 5.5, 6.7 Hz, 1H), 2.52 (br s, 1H), 2.47–2.41 (m, 1H), 2.32–2.26 (m, 1H); ¹³C NMR (125) MHz, CDCl₃): δ 137.7, 134.5, 134.4, 130.4, 128.5, 128.0, 127.9, 127.8, 117.5, 73.7, 72.0, 71.7, 71.2, 65.8, 38.1; HRMS calcd for $C_{16}H_{20}NaO_3$ [M + Na]⁺ 283.1310, Found: 283.1313.

1-((2R,5S,6R)-6-(benzyloxymethyl)-5-hydroxy-5,6-dihydro-2H-pyran-2-yl)propan-2-one (9): To a stirred solution of PdCl₂ (8 mg, 0.046 mmol) in DMF/H₂O (4:1, 2 mL) was added CuCl (91 mg, 0.92 mmol) and stirred under O₂ (balloon) for 1 h. Then a solution of olefin **8** (120 mg, 0.46 mmol), dissolved in DMF (1 mL), was added, and again stirred for 6 h under O₂. On completion of the reaction (TLC monitoring), the reaction mixture was poured into 1 N HCl (5 mL), followed by an extraction with ethyl acetate (3 × 5 mL). The combined organic extracts were washed with ice-water (1 × 10 mL), brine (1 × 10 mL) and then dried over Na₂SO₄. The solvent was removed under vacuum and crude residue was purified by column chromatography, to yield 98 mg (77%) of ketone **9** as a colorless oil: $R_f = 0.3$ (hexane/EtOAc = 3:1); $[\alpha]_D^{28} = -1.4$ (*c* 1.40, CH₂Cl₂); IR (neat) v_{max} : 3421, 2869, 1712, 1496, 1453, 1362, 1261, 1165, 1095, 1074 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.35–7.25 (m, 5H), 5.83 (ddd, J = 2.4, 4.6, 10.4 Hz, 1H), 5.78–5.74 (m, 1H), 4.66–4.62 (m, 1H), 4.56 (s, 2H), 4.08 (d, J = 5.8 Hz, 1H), 3.70–3.57 (m, 3H), 2.83 (dd, J = 8.2, 16.2 Hz, 1H), 2.69 (*br* s, 1H), 2.57 (dd, J = 5.5, 16.2 Hz, 1H), 2.17 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 206.4, 137.7, 129.8, 128.5, 127.9, 127.8, 73.8, 72.1, 71.0, 68.8, 65.4, 46.9, 30.8; HRMS calcd for C₁₆H₂₀NaO₄ [M + Na]⁺ 299.1259, Found: 299.1259.

N-((2R,3R,6S)-6-(Benzyloxymethyl)-2-(2-oxopropyl)-3,6-dihydro-2H-pyran-3-yl)-2,2,2-

trichloroacetamide (10): To a stirred solution of allylic alcohol 9 (110 mg, 0.40 mmol) in dry dichloromethane (3 mL) at 0 °C, was added trichloroacetonitrile (0.04 mL, 0.40 mmol), followed by DBU (0.06 mL, 0.40 mmol), and the mixture was stirred for 30 minutes at the same temperature. The solvent was removed by evaporation and the residue was passed through a silica plug followed by concentration of the filtrate. The crude trichloroacetimidate (R_f 0.6 in hexane/EtOAc = 4:1) was then dissolved in dry xylene (3 mL) and K₂CO₃ (5 mg, 0.04 mmol) was added to it. The resulting mixture was heated under reflux overnight. The solvent was then evaporated and the residue purified by column chromatography to afford 120 mg (72% over two steps) of the rearranged product 10 as a pale yellow liquid: $R_f = 0.7$ (hexane/EtOAc = 4:1); $[\alpha]_D^{28} = -84.0$ (c 0.25, CH₂Cl₂); IR (neat) v_{max} : 2922, 1710, 1499, 1062, 820 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.36–7.28 (m, 5H), 6.66 (d, J = 8.8 Hz, 1H), 6.02 (s, 2H), 4.60–4.51 (m, 3H), 4.43 (dd, J = 4.6, 6.1 Hz, 1H), 4.32–4.28 (m, 1H), 3.68 (dd, J = 7.0, 10.1 Hz, 1H), 3.56 (dd, J = 4.3, 10.1 Hz, 1H), 2.66 (dd, J = 7.6, 17.1 Hz, 1H), 2.58 (dd, J = 4.9, 17.1 Hz, 1H), 2.16 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 205.3, 162.0, 137.9, 131.5, 128.5, 127.8, 124.9, 73.6, 69.9, 67.9, 46.3, 44.7, 30.7; HRMS calcd for C₁₈H₂₀Cl₃NNaO₄ [M + Na]⁺ 442.0356, Found: 442.0352.

Benzyl (2R,3R,6S)-6-(benzyloxymethyl)-2-(2-oxopropyl)-3,6-dihydro-2H-pyran-3-ylcar-

bamate (11): The trichloroacetamide 10 (110 mg, 0.26 mmol) was dissolved in THF (1 mL), 6 N HCl (2 mL) was added, and the resulting solution heated under reflux overnight. Then the solution was cooled to 0 °C, quenched by the careful addition of saturated NaHCO₃ (5 mL), and extracted with EtOAc (3×5 mL). The extracts were dried over Na₂SO₄, and concentrated under vacuum. ($R_f = 0.2$ (hexane/EtOAc = 1:1)). The crude product was then dissolved in EtOAc (3 mL), benzyl chloroformate (0.14 mL, 0.52 mmol, 50% in toluene) was added followed by Na₂CO₃ (83 mg, 0.78 mmol), and the mixture stirred for 2 h at room temperature. The reaction mixture was diluted with 5 mL water and extracted with EtOAc (3 \times 5 mL). Extracts were washed with brine (1 \times 10 mL), dried over Na₂SO₄, and concentrated under vacuum. The crude residue was purified by column chromatography to yield 77 mg of 11 (74% over 2 steps) as a colorless oil: $R_f = 0.4$ (hexane/EtOAc = 4:1); $[\alpha]_D^{28} = -90.0$ (c 0.50, CH₂Cl₂); IR (neat) v_{max} : 3323, 2922, 1715, 1498, 1454, 1363, 1233, 1109, 1049 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.36–7.27 (m, 10H, aromatic), 5.99 (ddd, J = 2.1, 6.1, 10.1Hz, 1H, H-3), 5.87 (dd, J = 3.1, 10.1 Hz, 1H, H-4), 5.12–5.07 (m, 2H, NHCO₂CH₂Ph), 4.85 (d, J = 9.8 Hz, 1H, -NHCO), 4.58 (d, J = 12.2 Hz, 1H, OCH₂Ph), 4.52 (d, J = 12.2 Hz, 1H, OCH₂Ph), 4.41–4.38 (m, 1H, H-1), 4.35–4.32 (m, 1H, H-5), 4.04–4.00 (m, 1H, H-2), 3.64 (dd, J = 7.0, 10.4 Hz, 1H, H-6), 3.50 (dd, J = 4.6, 10.4 Hz, IH, H-6'), 2.62 (dd, J = 8.2, 16.8 Hz, 1H, H-1'), 2.55 (dd, J = 4.6, 16.8 Hz, 1H, H-1"), 2.11 (s, 3H, CH₃CO-); ¹³C NMR (125) MHz, CDCl₃): δ 206.1, 156.2, 138.0, 136.4, 129.7, 128.6, 128.4, 128.3, 128.1, 127.8, 127.7, 126.4, 73.5, 73.3, 70.0, 68.1, 67.0, 46.1, 45.1, 30.7; HRMS calcd for C₂₄H₂₈NO₅ [M + H]⁺ 410.1967, Found: 410.1967.

Benzyl (3a*R*,4*R*,6*R*,7*S*,7a*R*)-4-(benzyloxymethyl)-2,2-dimethyl-6-(2-oxopropyl)tetrahydro-3a*H*-[1,3]dioxolo[4,5-*c*]pyran-7-ylcarbamate (12):The olefin 11 (50 mg, 0.12 mmol) was dissolved in an acetone/H₂O/*t*-BuOH solvent system (3:1:1, 3 mL), *N*-methylmorpholine *N*-oxide (17 mg, 0.14 mmol) and a catalytic amount of OsO₄ (0.1 mL, 1% w/w soln in *t*-BuOH) were added in succession, and the mixture was stirred at room temperature for 24 h. On completion (TLC monitoring) the reaction was treated with a saturated Na₂S₂O₅ solution (3 mL) and then extracted with ethyl acetate (3 × 3 mL). Organic extracts were washed with brine (1 × 5 mL), dried over Na₂SO₄, and concentrated. The crude residue was used for the next step without purification: $R_f = 0.3$ (hexane/EtOAc = 1:1).

The crude diol was dissolved in dry CH₂Cl₂ (2 mL) and cooled to 0 °C. Then, 2,2dimethoxypropane (0.02 mL, 0.14 mmol) was added, followed by PTSA (2 mg, 0.01 mmol), and stirred at room temperature for 1 h. The reaction mixture was diluted with CH₂Cl₂ (2 mL) and a saturated NaHCO₃ solution (3 mL) was added. Extraction was carried out with CH₂Cl₂ (3 × 3 mL), and extracts were dried over Na₂SO₄. The removal of the solvent under vacuum provided a crude residue, which was purified by column chromatography to furnish 48 mg (82%) of the compound **12** as a colorless oil: $R_f = 0.4$ (hexane/EtOAc = 4:1); $[\alpha]_D^{28} = -6.7$ (*c* 0.15, CH₂Cl₂); IR (neat) v_{max} : 3331, 2924, 2854, 1715, 1521, 1454, 1381, 1214, 1055 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.38–7.26 (m, 10H, aromatic), 5.09 (s, 2H, -CO₂CH₂Ph), 5.05 (d, *J* = 7.3 Hz, 1H, -N*H*), 4.63 (m, 1H, H-1), 4.57 (d, *J* = 12.2 Hz, 1H, -OCH₂Ph), 4.52 (d, *J* = 12.2 Hz, 1H, -OCH₂Ph), 4.32 (dd, *J* = 2.4, 7.3 Hz, 1H, H-4), 4.26–4.25 (m, 1H, H-5), 3.94-3.92 (m, 1H, H-3), 3.68–3.60 (m, 3H, H-2, H-6, H-6'), 2.64 (dd, *J* = 8.7, 15.9 Hz, 1H, H- 1'), 2.45 (dd, J = 5.5, 15.9 Hz, 1H, H-1"), 2.13 (s, 3H, CH₃CO-), 1.52 (s, 3H), 1.25 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 205.7, 155.9, 138.1, 136.1, 128.6, 128.5, 128.4, 128.3, 128.2, 127.7, 109.3, 73.5, 71.5, 70.4, 69.5, 67.2, 65.5, 52.7, 45.5, 30.3, 26.9, 24.3; HRMS calcd for C₂₇H₃₃NNaO₇ [M + Na]⁺ 506.2155, Found: 506.2155. **Copies of NMR spectra:**



Figure S1: ¹H NMR (500 MHz) spectrum of compound **2g**.



Figure S2: ¹³C NMR (125 MHz) spectrum of compound 2g.



Figure S3: ¹H NMR (500 MHz) spectrum of compound 2i.



Figure S4: ¹³C NMR (125 MHz) spectrum of compound 2i.



Figure S5: ¹H NMR (500 MHz) spectrum of compound 2l.



Figure S6: ¹³C NMR (125 MHz) spectrum of compound 2l.



Figure S7: ¹H NMR spectrum (500 MHz) of compound **3**.



Figure S8: ¹³C NMR spectrum (100 MHz) of compound 3.



Figure S9: ¹H NMR spectrum (500 MHz) of compound **4**.



Figure S10: ¹³C NMR spectrum (100 MHz) of compound 4.



Figure S11: ¹H NMR spectrum (500 MHz) of compound **5**.



Figure S12: ¹³C NMR spectrum (100 MHz) of compound **5**.



Figure S13: ¹H NMR spectrum (500 MHz) of compound **6**.



Figure S14: ¹³C NMR spectrum (100 MHz) of compound **6**.



Figure S15: ¹H NMR spectrum (500 MHz) of compound **7**.



Figure S16: ¹³C NMR spectrum (100 MHz) of compound **7**.



Figure S17: ¹H NMR (500 MHz) spectrum of compound **8**.



Figure S18: ¹³C NMR (500 MHz) spectrum of compound 8.



Figure S19: ¹H NMR (500 MHz) spectrum of compound 9.



Figure S20: ¹³C NMR (125 MHz) spectrum of compound 9.



Figure S21: ¹H NMR (500 MHz) spectrum of compound 10.



Figure S22: ¹³C NMR (125 MHz) spectrum of compound 10.



Figure S23: ¹H NMR (500 MHz) spectrum of compound 11.



Figure S24: ¹³C NMR (125 MHz) spectrum of compound 11.



Figure S25: ¹H-¹H COSY spectrum of compound **11**.



Figure S26: ¹H NMR (500 MHz) spectrum of compound 12.



Figure S27: ¹³C NMR (125 MHz) spectrum of compound 12.

Figure S28: ¹H-¹H COSY (500 MHz) spectrum of compound **12**.

Figure S30: nOe spectrum (irradiation of H-2) of compound 12.

Figure S31: Homonuclear decoupling spectrum (400 MHz, H-3) of compound 12.

Figure S32: Homonuclear decoupling spectrum (400 MHz, H-1') of compound 12.